Tagrix 80
The indications for Tagrix 80 mg
Non-small cell lung cancer (NSCLC) with metastatic epidermal growth factor receptor (EGFR) mutation T790M detected by an FDA-approved test can be treated with Tagrix 80 mg if the disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
A class of therapeutics
Cytotoxic Chemotherapy
Pharmacology
Tagrix 80 mg binds to mutant EGFR forms (T790M, L858R, and exon 19 deletion) present in non-small cell lung cancer (NSCLC) tumors following first-line EGFR-TKI treatment. This third-generation tyrosine kinase inhibitor targets the gatekeeper T790M mutation, which increases the ATP binding activity of EGFR and results in a poor prognosis for patients with late-stage cancer. Further, Tagrix 80 mg spares wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.
The dosage of Tagrix 80 mg
As long as disease progression does not occur or unacceptable toxicity does not occur, Tagrix 80 mg should be taken once daily until it is no longer effective. With or without food, Tagrix 80 mg can be taken. If you miss a dose of Tagrix 80 mg, do not make up the missed dose and take your next dose as scheduled.
Ask Price